Last update 11 Nov 2024

BAY-867548

Last update 11 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals

Synonyms

68Ga-Bombesin, [(68)Ga]-labelled bombesin, [68Ga]RM2

+ [9]

Target

GRPR

Mechanism

GRPR modulators(Gastrin releasing peptide receptor modulators), PET imaging(Positron-emission tomography enhancers)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Prostatic CancerAdenocarcinoma of prostateMetastatic Prostate Carcinoma

Inactive Indication

Diagnostic agents

Originator Organization

University of Bern

Active Organization

Lantheus Holdings, Inc.

Bayer AG

Stanford University

Inactive Organization

Life Molecular Imaging Ltd.

National Institutes of Health

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure

Molecular FormulaC78H115GaN20O19

InChIKeyHPQFXKMKTOABLV-ZQSXMSGHSA-K

CAS Registry1444870-03-4

Boost your research with our XDC technology data.

view full example data

Gene Sequence

Sequence Code 19351754

Clinical Trials associated with BAY-867548

NCT05889728 / RecruitingPhase 2IIT

Assessment of the Diagnostic and Theranostic Potential of Ga Bombesin PET/CT (NeoB) Imaging for Staging of ER/PR + HER2- Breast Cancer Patients With Metastatic Disease: Comparison to Conventional Imaging

This phase IIb pilot study will enrol 20 patients (women) presenting with metastatic breast cancer (ER/PR + HER2- on histology) who require imaging for staging or re-staging of their disease.

Start Date20 Feb 2023

Sponsor / Collaborator

St. Vincent's Hospital Sydney Pty Ltd.

[+1]

NCT06484361 / RecruitingPhase 2

Phase II Monocentric Study to Evaluate a Novel Approach for Staging Prostate Cancer Patients by Using a Fully Integrated Hybrid PET/MRI

The main goal of this phase II clinical trial is to define a novel approach of staging prostate cancer (PCa) patients by using a fully integrated positron emission tomography/ magnetic resonance imaging (PET/MRI) system with 68Ga-prostate specifica membrane antigen (PSMA) and 68Ga-RM2 (bombesin antagonist).
50 patients with biopsy proven PCa will be studied by PET/MRI with 68Ga-PSMA and with 68Ga-RM2 and then will undergo prostatectomy and pelvic lymphadenectomy.

Start Date09 Sep 2020

Sponsor / Collaborator

IRCCS San Raffaele Roma Srl

NCT05806853 / CompletedPhase 2IIT

Phase II Prospective Monocentric Study on Prostate Cancer Restaging by Using PET/MR With Innovative Radiotracers

The overall goal is to provide an innovative approach to restage patients with biochemical recurrence of prostate cancer by using hybrid PET/MR with innovative radiotracers (68Ga-PSMA and 68Ga-RM2)

Start Date03 Jun 2020

Sponsor / Collaborator

Ospedale San Raffaele Srl

100 Clinical Results associated with BAY-867548

100 Translational Medicine associated with BAY-867548

100 Patents (Medical) associated with BAY-867548

279

Literatures (Medical) associated with BAY-867548

01 Dec 2024·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Radiotracers for in situ infection imaging: Experimental considerations for in vitro microbial uptake of gallium-68-labeled siderophores

Article

Author: Darwesh, Afnan M.F. ; Price, Nicholas M. ; Cooper, Margaret S. ; Abbate, Vincenzo ; Lyons, Oliver ; Schelenz, Silke ; Cooper, Margaret S ; Price, Nicholas M ; Hider, Robert C. ; Akter, Asma ; Blower, Philip J. ; Blower, Philip J ; Hider, Robert C ; Darwesh, Afnan M F ; Mehra, Varun

In vitro screening of gallium-68(⁶⁸Ga)-siderophores in pathogens relevant to infections is valuable for determining species specificity, their effect on cell viability, and potential clinical applications. As the recognition and internalization of siderophores relies on the presence of receptor- and/or siderophore-binding proteins, the level of uptake can vary between species. Here, we report in vitro uptake validation in Escherichia coli with its native siderophore, enterobactin (ENT) ([⁶⁸Ga]Ga-ENT), considering different experimental factors. Compared with other reporting methods of uptake, '% Added dose/10⁹ CFU/mL (% AD/10⁹ CFU/mL),' considering the total viable count, showed a better comparison among microbial species. Later, in vitro screening with [⁶⁸Ga]Ga-desferrioxamine B (DFO-B) showed high uptake by Staphylococcus aureus and S. epidermidis; moderate uptake by Pseudomonas aeruginosa; poor uptake by E. coli, Candida albicans, and Aspergillus fumigatus; and no uptake by Enterococcus faecalis and C. glabrata. Except for S. epidermidis, [⁶⁸Ga]Ga-DFO-B did not reduce the cell viability.

04 Nov 2024·EJNMMI Physics

Bidirectional dynamic frame prediction network for total-body [⁶⁸Ga]Ga-PSMA-11 and [⁶⁸Ga]Ga-FAPI-04 PET images.

Article

Author: Yang, Qianyi ; Liang, Dong ; Yang, Yongfeng ; Li, Wenbo ; Zhao, Wenjie ; Chen, Ruohua ; Huang, Zhenxing ; Gao, Yunlong ; Yang, Xinlan ; Liu, Jianjun ; Hu, Zhanli ; Zheng, Hairong ; Chen, Zixiang

PURPOSE:

Total-body dynamic positron emission tomography (PET) imaging with total-body coverage and ultrahigh sensitivity has played an important role in accurate tracer kinetic analyses in physiology, biochemistry, and pharmacology. However, dynamic PET scans typically entail prolonged durations ([Formula: see text]60 minutes), potentially causing patient discomfort and resulting in artifacts in the final images. Therefore, we propose a dynamic frame prediction method for total-body PET imaging via deep learning technology to reduce the required scanning time.

METHODS:

On the basis of total-body dynamic PET data acquired from 13 subjects who received [⁶⁸Ga]Ga-FAPI-04 (⁶⁸Ga-FAPI) and 24 subjects who received [⁶⁸Ga]Ga-PSMA-11 (⁶⁸Ga-PSMA), we propose a bidirectional dynamic frame prediction network that uses the initial and final 10 min of PET imaging data (frames 1-6 and frames 25-30, respectively) as inputs. The peak signal-to-noise ratio (PSNR) and structural similarity index measure (SSIM) were employed as evaluation metrics for an image quality assessment. Moreover, we calculated parametric images (⁶⁸Ga-FAPI: [Formula: see text], ⁶⁸Ga-PSMA: [Formula: see text]) based on the supplemented sequence data to observe the quantitative accuracy of our approach. Regions of interest (ROIs) and statistical analyses were utilized to evaluate the performance of the model.

RESULTS:

Both the visual and quantitative results illustrate the effectiveness of our approach. The generated dynamic PET images yielded PSNRs of 36.056 ± 0.709 dB for the ⁶⁸Ga-PSMA group and 33.779 ± 0.760 dB for the ⁶⁸Ga-FAPI group. Additionally, the SSIM reached 0.935 ± 0.006 for the ⁶⁸Ga-FAPI group and 0.922 ± 0.009 for the ⁶⁸Ga-PSMA group. By conducting a quantitative analysis on the parametric images, we obtained PSNRs of 36.155 ± 4.813 dB (⁶⁸Ga-PSMA, [Formula: see text]) and 43.150 ± 4.102 dB (⁶⁸Ga-FAPI, [Formula: see text]). The obtained SSIM values were 0.932 ± 0.041 (⁶⁸Ga-PSMA) and 0.980 ± 0.011 (⁶⁸Ga-FAPI). The ROI analysis conducted on our generated dynamic PET sequences also revealed that our method can accurately predict temporal voxel intensity changes, maintaining overall visual consistency with the ground truth.

CONCLUSION:

In this work, we propose a bidirectional dynamic frame prediction network for total-body ⁶⁸Ga-PSMA and ⁶⁸Ga-FAPI PET imaging with a reduced scan duration. Visual and quantitative analyses demonstrated that our approach performed well when it was used to predict one-hour dynamic PET images. https://github.com/OPMZZZ/BDF-NET .

01 Nov 2024·EUROPEAN JOURNAL OF PEDIATRICS

Diagnostic efficacy of [68Ga]Ga-NY104 PET/CT to identify clear cell renal cell carcinoma

Article

Author: Bai, Chunmei ; Liu, Meixi ; Cheng, Yuejuan ; Huo, Li ; Zheng, Guoyang ; Zhu, Wenjia ; Li, Xiaoyuan ; Zhang, Yushi ; Yan, Xinchun

PURPOSE:

Most clear cell renal cell carcinoma (ccRCC) overexpresses carbonic anhydrase IX (CAIX). [⁶⁸Ga]Ga-NY104 is a small-molecule PET agent selectively targeting CAIX. This study aims to assess the efficacy of [⁶⁸Ga]Ga-NY104 PET/CT to identify ccRCC.

MATERIALS AND METHODS:

Participants were prospectively recruited in the study (ClinicalTrials.gov: NCT05902377). They were further divided into two groups: group 1, patients with primary renal mass who were scheduled for surgery, group 2, patients with suspected/confirmed metastatic ccRCC. All patients underwent [⁶⁸Ga]Ga-NY104 PET/CT.

RESULTS:

A total of 47 patients (mean age, 58.8 years ± 13.5, 34 men) were recruited, including 20 patients in group 1 and 27 patients in group 2. The patient-level sensitivity, specificity, and accuracy of [⁶⁸Ga]Ga-NY104 PET scan was 62%, 33%, 58% for group 1 and 95%, 100%, 96% for group 2. [⁶⁸Ga]Ga-NY104 PET identified additional 26 disease regions in 67% (14/21) of patients that were previously unknown. The tumor uptake was correlated with immunohistochemical staining results.

CONCLUSIONS:

^{[68Ga]Ga-NY104} PET/CT has a high diagnostic efficacy for patients with metastatic ccRCC, while it might be of limited value in the diagnosis of primary ccRCC.

News (Medical) associated with BAY-867548

04 Apr 2024

·www.biospace.com

RLS Radiopharmacies Partners with Eckert & Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

RLS expands rCDMO capabilities with Eckert & Ziegler's GalliaPharm® generators for improved patient diagnostics RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler (ISIN DE0005659700, SDAX). Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals. Ga-68 is crucial for Positron Emission Tomography (PET) imaging and plays a pivotal role in the accurate diagnosis and subsequent treatment planning for patients with neuroendocrine tumors and prostate cancer. “To help meet the ever-increasing demand for precision diagnostics in cancer treatment, we are collaborating with Eckert & Ziegler to place advanced Ga-68 radiolabeling technology into the hands of all our skilled radiopharmacists nationwide," said RLS CEO Stephen Belcher. “A powerful diagnostic isotope, Gallium has an extremely short half-life, necessitating the need for Ga-68-based radiopharmaceuticals to be produced within minutes of patient dosing. By bringing Eckert & Ziegler’s GalliaPharm® generators into our network, we are closing the patient care gap in many parts of the U.S. This signifies a major leap forward in our commitment to advancing healthcare and improving patient outcomes through cutting-edge radiopharmaceuticals." To date, RLS has installed Eckert & Ziegler’s GalliaPharm® generators within most of its locations and anticipates the remaining radiopharmacies will be operational by the end of June. All of RLS’s radiopharmacies house cutting-edge clean rooms and are fully equipped and aligned to USP <797>, USP <825> and ISO 14644-1 compliance standards, which guarantees Ga-68-radiolabeled products are produced to the highest standard possible. Additionally, each location is led by experienced nuclear pharmacists, who, along with nuclear technicians, in-house couriers and a robust delivery fleet, ensure every order is meticulously prepared, dispensed and distributed. RLS is also investing in the future by building a national distributed rCDMO network. 80,000 sq. ft. of space across eight of its pharmacies will be used for radiopharmaceutical development, manufacturing and the production of medical isotopes such as Gallium-68, Actinium-225 and Lutetium-177. RLS now offers Ga-68-based radiolabeling, custom compounding, patient dose preparation and last-mile delivery. "We are pleased to be a trusted partner to RLS in their strategic decision to improve the nationwide supply of the important Ga-68-based diagnostics and to equip their radiopharmacies with our GalliaPharm®," said Jay Simon, managing director of Eckert & Ziegler Radiopharma, Inc. "The demand for radiopharmaceuticals continues to grow in the U.S. and around the world, with many promising drugs in clinical trials. As the number of products increases, the flexibility that our generator provides in the production of Ga-68 will be an even greater asset than before." Ga-68 from GalliaPharm® generators is used in the preparation of radiodiagnostics for neuroendocrine tumors and prostate cancer (Ga-68-PSMA) in countries all around the world. The generator offers a low-cost alternative for the radiolabeling of biomolecules with Gallium-68 in PET, an imaging examination method used to detect the presence or absence of diseased tissue. PET Imaging is primarily used in the diagnosis of cancer, heart attacks or neurological diseases. Radioisotopes such as Fluorine-18 can be used alternatively but require investments of millions of dollars in large-scale equipment (cyclotrons). The Ge-68/Ga-68 generator on the other hand, is an easily transportable, small metal box and can be obtained much more cost-efficient, leading to cost reductions in nuclear medicine clinics and practices while increasing flexibility. For more information about RLS Radiopharmacies, please visit rls.bio.

Diagnostic Reagents

06 Jun 2022

·www.prnewswire.com

IND approval from the US FDA for Phase II SAR-Bombesin imaging trial in prostate cancer

Highlights IND approval received for SAR-Bombesin product, enabling a Phase II "SABRE" imaging trial to detect prostate cancer in up to 50 PSMA-negative participants in the US Approximately 20% of prostate cancer patients with biochemical recurrence (BCR) are PSMA-PET negative and therefore unsuitable for the currently approved PSMA targeting agents, presenting an opportunity to target these cancers with Clarity's SAR-Bombesin product SYDNEY, June 6, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address growing medical needs in oncology, announces the approval of its Investigational New Drug (IND) application by the United States Food and Drug Administration (US FDA) to evaluate its SAR-Bombesin product as an imaging agent in prostate cancer patients that are Prostate-Specific Membrane Antigen (PSMA)-negative. Clarity's Executive Chairman, Dr Alan Taylor, commented, "Receiving clearance from the FDA on the imaging trial with SAR-Bombesin is yet another significant milestone for Clarity. It shows our ability to develop cutting-edge theranostics from the lab, through preclinical studies and into clinical trials, with SAR-Bombesin being Clarity's fourth IND across five products which are clear for investigation in the US." This IND gives Clarity clearance to proceed with a US-based Phase II 64Cu SAR-Bombesin Positron Emission Tomography (PET) imaging trial in participants with PSMA-negative biochemical recurrence (BCR) of prostate cancer following definitive therapy (such as surgery or radiation). SABRE, which derives from "Copper-64 SAR-Bombesin in Biochemical REcurrence of Prostate Cancer trial", is a multi-center, single arm, non-randomised, open-label trial in up to 50 PSMA-negative patients with known or suspected prostate cancer. The primary objectives of the trial are to investigate the safety and tolerability of 64Cu SAR-Bombesin, as well as its ability to correctly detect the recurrence of prostate cancer. The SABRE trial builds upon the promising clinical data from the pilot trial assessment of 64Cu SAR-Bombesin in breast cancer led by Prof Louise Emmett of St Vincent's Hospital Sydney. The data from this trial was recently presented at the prestigious American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The SABRE trial was developed in response to the strong demand for this product from clinicians with prostate cancer patients whose cancer was not visible with currently approved PSMA diagnostic agents or conventional imaging (such as CT and/or MRI). Their patients were successfully imaged with 64Cu SAR-Bombesin under a Special Access Scheme. Approximately 20% of prostate cancers with BCR are PSMA-PET negative1-4. These patients are therefore unlikely to respond to therapeutic PSMA-targeted products and currently have few treatment options available to them. Given the prostate cancer indication is one of the largest in oncology, there is a significant unmet medical need in this segment. The SAR-Bombesin product targets the Gastrin Releasing Peptide receptor (GRPr) found on prostate and many other cancers. As such, the product could offer valuable imaging and therapeutic options for not only PSMA negative patients, but also the large number of patients that have the target receptor on their cancers. "We look forward to further progressing the development of SAR-Bombesin and hope it will provide a new and effective diagnostic option for prostate cancer patients. Building on the promising clinical and preclinical data acquired to date, we are also planning an IND submission for a theranostic trial in prostate cancer participants, using 67Cu SAR-Bombesin therapy paired with the imaging agent, 64Cu SAR-Bombesin. Combined with the clinical, environmental and logistical benefits enabled by the copper isotope pairing, SAR-Bombesin has potential to provide this large patient population with accurate and precise detection and treatment of prostate cancer. We anticipate the SABRE trial to commence shortly and the theranostic trial to commence in 2023," Dr Taylor added. This announcement has been authorised for release by the Executive Chairman. For more information, please contact: About Clarity Pharmaceuticals Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults. About SAR-Bombesin SAR-Bombesin is a highly targeted pan-cancer radiopharmaceutical with broad cancer application. It targets the gastrin-releasing peptide receptor (GRPr) present on cells of a range of cancers, including but not limited to prostate, breast and ovarian cancers. GRPr is found in approximately 75-100% of prostate cancers, including prostate cancers that don't express PSMA (PSMA-negative)5-9. The product utilises Clarity's proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-Bombesin is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu for therapy). About Prostate Cancer Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death worldwide10. The National Cancer Institute estimates in 2022 there will be 268,490 new cases of prostate cancer in the US and around 34,500 deaths from the disease11. References Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268. Ferraro DA, Rüschoff JH, Muehlematter UJ, et al. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET. Theranostics. 2020;10(14):6082-6094. Baratto L, Song H, Duan H, et al. PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2021;62(11):1545-1549. Mapelli P, Ghezzo S, Samanes Gajate AM, et al. 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data. Cancers (Basel). 2022;14(2):334. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer research. 1999;59(5):1152-1159. Fleischmann A, Waser B, Reubi JC. High expression of gastrin-releasing peptide receptors in the vascular bed of urinary tract cancers: promising candidates for vascular targeting applications. Endocrine-related cancer. 2009;16(2):623-633. Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. The Prostate. 2009;69(10):1101-1108. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res. 2002;8(4):1139-1146. Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. The Prostate. 2000;42(4):295-303. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries American Cancer Society, Cancer Statistics Center, SOURCE Clarity Pharmaceuticals

Diagnostic ReagentsASCOmRNA

100 Deals associated with BAY-867548

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adenocarcinoma of prostate	Phase 3	US	Stanford University	16 Nov 2015
Prostatic Cancer	Phase 3	-	Bayer AG	-
Metastatic Prostate Carcinoma	Phase 2	US	Lantheus Holdings, Inc.	-
Diagnostic agents	Phase 1	FI	Life Molecular Imaging Ltd.	01 Nov 2010
Diagnostic agents	Phase 1	DE	Life Molecular Imaging Ltd.	01 Nov 2010
Diagnostic agents	Phase 1	CH	Life Molecular Imaging Ltd.	01 Nov 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03113617 (CTgov)	Phase 2	Adenocarcinoma of prostate	44	Computed Tomography+Gallium Ga 68-labeled GRPR Antagonist BAY86-7548	bvacpzbykk(yfewpyqbay) = erpixsmtmg jeuvmeyczx (nlosjuahkn, qvegmyoztc - eormpetjod) View more	-	24 May 2023
NCT02624518 (CTgov)	Phase 2/3	Adenocarcinoma of prostate	122	Positron Emission Tomography+68Ga-RM2	wpdemnixmq(jqmzeitrtf) = fhpychosgd ylzfayhnnh (vfgkjvvfqz, zqwotzzcca - mfybxzygfq) View more	-	10 Apr 2023
NCT02624518 (ASCO2020) Manual	Phase 2/3	Non-metastatic prostate cancer PSA	114	68Ga-RM2 +PET	vnvvtzkjfc(jczoaetzve) = gjoflzdgyb glohogvtng (jlucdykrsn ) View more	Positive	29 May 2020
NCT02624518 (ASCO2020) Manual	Phase 2/3	Non-metastatic prostate cancer PSA	114	68Ga-PSMA11 +PET	vnvvtzkjfc(jczoaetzve) = nscajsehff glohogvtng (jlucdykrsn ) View more	Positive	29 May 2020
SNMMI2020	Not Applicable	Prostatic Cancer	-	68Ga-RM268 Ga-RM2 (68Ga-RM2 PET/CT)	gbdbdjqwfx(xwfunfflyc) = khwczpeypo jznuaomoux (edcfjchtrb ) View more	-	15 May 2020
SNMMI2020	Not Applicable	Prostatic Cancer	-	68 Ga-RM2 (mpMRI)	gbdbdjqwfx(xwfunfflyc) = zqumfstwbf jznuaomoux (edcfjchtrb ) View more	-	15 May 2020
SNMMI2019	Not Applicable	Recurrent Prostate Carcinoma prostate specific antigen \| PSA velocity	84	68Ga-RM268 Ga-RM2 (68Ga-RM2 PET)	zygehypnin(gwjvanhwct) = oobdvonrrn hhxcqzgpfz (apwjoneyps ) View more	Positive	21 May 2019
Pubmed \| Eur Urol Oncol	Not Applicable	Prostatic Cancer GRPR- \| PSMA	16	68Ga-RM2BAY86-7548 (68Ga-RM2 PET/CT)	gcnzxsbosi(zpprnzvgpf) = eltsboneyg tpngprrbnk (kwsqzzmlav ) View more	Positive	01 Mar 2019
SNMMI2018	Not Applicable	Prostatic Cancer	-	68 Ga-RM2 (GRPr expression)	ezoxoawqqa(cewltjocus) = qeahenmylg ajucmccxrf (gvfooxdbur )	-	23 May 2018
SNMMI2018	Not Applicable	Prostatic Cancer	-	68 Ga-RM2 (PSMA expression)	ijefxqjmli(wsmhpmgzgh) = qobdagmycc jzbedixnlp (slpdserpbi )	-	23 May 2018
SNMMI2018	Not Applicable	Recurrent Prostate Carcinoma	-	68Ga-RM268 Ga-RM2 (68Ga-RM2 PET)	nnwtlurrvt(ryfvsqqgme) = qrzldhuvea hjuxswujtu (xegreecspj, 0.04 - 1.9) View more	-	23 May 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis